TriC has also shown additive or synergistic effects with other therapies (e.g., increasing sensitivity to gemcitabine in pancreatic and lung cancer cells [57, 58] and synergizing with ABT‐199, the FDA‐approved BCL‐2 inhibitor, in AML cells [21]). Here, BCL2 is linked to lung carcinoma.